Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price traded up 1.8% during mid-day trading on Thursday. The company traded as high as $30.44 and last traded at $30.3950. 27,525,237 shares traded hands during trading, a decline of 31% from the average daily volume of 39,913,023 shares. The stock had previously closed at $29.85.
Key Stories Impacting Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer completed a Phase 1 study of PF-07999415, providing an early development milestone and potentially adding value to its pipeline. The update does not yet establish efficacy or commercial potential, but it offers investors another clinical program to monitor. Pfizer PF-07999415 Phase 1 update
- Positive Sentiment: Pfizer signed a research and licensing agreement with Enodia Therapeutics focused on Sec61 inhibitors. The deal gives Pfizer rights to discover, develop and potentially commercialize candidates from Enodia’s platform, supporting efforts to replenish its drug pipeline through external innovation. Pfizer Enodia Sec61 collaboration
- Neutral Sentiment: A Swedish real-world study of Pfizer’s Ibrance is supplying additional evidence about the product’s use in clinical practice. The update may help support the franchise, but the available report does not indicate a material change to revenue expectations. Pfizer Swedish Ibrance study
- Neutral Sentiment: Pfizer’s roughly 5.7% dividend yield remains attractive to income investors, but comparisons with Bristol Myers Squibb and Merck emphasize that the high payout may reflect concerns about earnings consistency and dividend coverage. Pfizer dividend comparison
- Negative Sentiment: Pfizer is being pulled into a broader selloff involving Moderna and Merck after investors reacted negatively to melanoma-vaccine results that were positive but apparently below elevated expectations. The episode is weighing on sentiment across pharmaceutical and biotechnology stocks, even though Pfizer is not the developer of Moderna’s vaccine. Biotech selloff affecting Pfizer
- Negative Sentiment: Higher interest rates can make Pfizer’s high-yield dividend less competitive relative to bonds and increase pressure on valuation, particularly while the company works through uneven revenue trends and post-pandemic portfolio changes. Interest rates and Pfizer dividend stocks
Wall Street Analyst Weigh In
Several research analysts recently issued reports on PFE shares. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. JPMorgan Chase & Co. lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. HSBC increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. Finally, Cantor Fitzgerald increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.72.
View Our Latest Research Report on PFE
Pfizer Stock Performance
The stock has a market cap of $171.19 billion, a P/E ratio of 39.52, a P/E/G ratio of 2.07 and a beta of 0.32. The company has a fifty day moving average price of $28.33 and a 200 day moving average price of $26.63. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.
Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the business earned $0.78 EPS. Pfizer’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 5.7%. Pfizer’s payout ratio is presently 226.32%.
Hedge Funds Weigh In On Pfizer
Several large investors have recently added to or reduced their stakes in PFE. Russell Investments Group Ltd. increased its stake in Pfizer by 15.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after acquiring an additional 745,213 shares during the last quarter. Handelsbanken Fonder AB raised its holdings in shares of Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after buying an additional 232,528 shares in the last quarter. Leuthold Group LLC bought a new stake in Pfizer in the 2nd quarter worth approximately $4,887,000. Park National Corp OH boosted its stake in shares of Pfizer by 332.1% in the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after purchasing an additional 186,053 shares in the last quarter. Finally, 111 Capital purchased a new stake in Pfizer during the second quarter valued at about $3,706,000. Institutional investors own 68.36% of the company’s stock.
About Pfizer
Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.
The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.
Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.
Read More
- Five stocks we like better than Pfizer
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
